DAX23.667 +0,2%ESt505.465 -0,1%Top 10 Crypto15,36 -1,7%Dow46.121 -0,4%Nas22.498 -0,3%Bitcoin95.011 -1,6%Euro1,1747 +0,1%Öl69,22 +0,2%Gold3.741 +0,1%

Navidea Biopharmaceuticals Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

0,0450 EUR -0,0525 EUR -53,85 %

25.10.2023

BMN

Navidea Biopharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Bei einem anderen Broker handeln

Smartphone

Marktkap.0,01 Mio. EUR

WKNA2PH4J

ISINUS63937X2027

SymbolNAVB

Navidea Biopharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

03.07.24BusinesswireNavidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024

21.06.24BusinesswireNavidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024

27.01.24BusinesswireNavidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations

WerbungNavidea Biopharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

01.12.23BusinesswireNavidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release

06.10.23BusinesswireNavidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock

10.08.23BusinesswireNavidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel

31.07.23BusinesswireNavidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities

29.07.23BusinesswireNavidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination

27.07.23BusinesswireNavidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

13.07.23BusinesswireNavidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down

30.06.23BusinesswireNavidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets

16.06.23BusinesswireNavidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock

16.06.23BusinesswireNavidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment

07.06.23BusinesswireNavidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

02.06.23BusinesswireNavidea Biopharmaceuticals, Inc. Receives NYSE American Notice

01.06.23BusinesswireNavidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down

23.05.23BusinesswireNavidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market

11.05.23BusinesswireNavidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer

08.05.23BusinesswireNavidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications

27.04.23BusinesswireNavidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit

13.04.23BusinesswireNavidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694

30.03.23BusinesswireNavidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down

21.03.23BusinesswireNavidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results

15.03.23BusinesswireNavidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update

03.01.23BusinesswireNavidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline

01.12.22BusinesswireNavidea Biopharmaceuticals Files Appeal in CRG Case

28.11.22BusinesswireNavidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis

14.11.22BusinesswireNavidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results

07.11.22BusinesswireNavidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

04.11.22BusinesswireNavidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update

05.10.22BusinesswireNavidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

30.09.22BusinesswireNavidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders

Navidea Biopharmaceuticals News

Navidea Biopharmaceuticals News: auf dieser Seite finden Sie alle Navidea Biopharmaceuticals News und Nachrichten zur Navidea Biopharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Navidea Biopharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Navidea Biopharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.